ACUTE BIPHENOTYPIC LEUKEMIA

This study is testing a combination of four chemotherapy drugs (cladribine, idarubicin, cytarabine, and venetoclax) to see how well they work against aggressive forms of blood cancer, including acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), and chronic my…

This study tests whether combining two medicines—enasidenib and azacitidine—can help control acute myeloid leukemia that has returned or hasn't responded to previous treatments. It's for patients whose cancer has a specific genetic change called an IDH2 mutation. Researchers want…

This study is testing whether removing a specific type of immune cell (called naive T cells) from a donor's stem cells before transplant can prevent chronic graft-versus-host disease in children and young adults with blood cancers. Chronic graft-versus-host disease is a serious c…

This early-stage study is testing the safety and feasibility of using bone marrow from deceased donors for patients with various blood cancers like leukemia and lymphoma. The goal is to see if this type of transplant can help patients when a living donor isn't available. Research…

This study is testing a new combination of cancer drugs for adults with aggressive forms of acute myeloid leukemia (AML) and related blood cancers that are newly diagnosed as high-risk or have come back after previous treatment. The goal is to find the safest and most effective d…

This study tests a personalized immune cell therapy for patients with blood cancers like leukemia, lymphoma, and myeloma. After receiving chemotherapy and a cord blood transplant, patients get infusions of natural killer (NK) cells—immune cells that may kill remaining cancer cell…

This early-stage trial is testing a new cell therapy for children and adults whose leukemia has come back or persists after a donor stem cell transplant. Doctors take immune cells (T cells) from the original donor, genetically modify them to better recognize and attack the patien…